STAA Earnings Prediction
The chart below shows how STAA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, STAA sees a +3.17% change in stock price 10 days leading up to the earnings, and a -4.22% change 10 days following the report. On the earnings day itself, the stock moves by +0.20%. This data can give you a slight idea of what to expect for the next quarter's release.
STAA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
48.95M
-35.82%
-44.75%
Gross Margin
64.65%
-18.80%
-16.38%
Operating Margin
-57.02%
-518.04%
-989.55%
Net Margin
-69.92%
-787.51%
-720.41%
EPS
-0.69
-531.25%
-445.00%
No Data Available
STAA Earnings Analysis
STAAR Surgical Co Corporation (STAA.O) Earnings Conference Call
Positive
International Sales Surge: ICL sales outside of China reached $152 million, reflecting a remarkable growth of 1713% in the fourth quarter and fiscal year 2024, demonstrating strong market share gains despite challenges in China.
Americas Sales Surge: ICL sales in the Americas grew by 22% in the fourth quarter and 15% for the fiscal year, significantly outpacing the overall U.S. refractive market, which declined by 20% in the fourth quarter.
EMEA Sales Growth: In EMEA, ICL sales increased by 9% in the fourth quarter and 10% for fiscal year 2024, driven by strong performance in European distributor markets, showcasing resilience amid geopolitical challenges.
APAC Sales Growth: ICL sales in APAC, excluding China, grew by 20% in the fourth quarter and 14% for fiscal year 2024, with notable contributions from Japan and South Korea, indicating robust demand in these regions.
Strong Cash Position: The company ended fiscal year 2024 with $230.5 million in cash and cash equivalents, maintaining a strong balance sheet with no debt, positioning it well for future growth opportunities.
Negative
Net Sales Decline: Net sales for fiscal 2024 were approximately $314 million, a decline of 3% from $322.4 million in fiscal 2023, primarily due to weak consumer sentiment and spending in China.
China Sales Performance: ICL sales in China for the fourth quarter were $7.5 million, and for the full year, they were $161 million, down 13% year over year, significantly impacted by a $27.5 million order that was shipped but not recognized as revenue due to extended payment terms.
Net Loss Decline: The company reported a net loss of $20.2 million for fiscal 2024 compared to a net income of $21.3 million in fiscal 2023, indicating a substantial decline in profitability.
Gross Margin Decline: Gross margin for the full year fiscal 2024 decreased by 210 basis points, primarily due to costs associated with the unrecognized revenue from the December shipment to China and elevated period costs from manufacturing expansions.
Fiscal 2025 EBITDA Outlook: The outlook for fiscal 2025 anticipates an adjusted EBITDA loss of approximately $50 million to $15 million, reflecting ongoing challenges in the China market and a projected decline in overall refractive procedure volumes.
STAA FAQs
How does STAA typically perform around its earnings report dates?
Is STAAR Surgical Co (STAA) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
STAA Earning Call Sentiment
Earnings call transcript: STAAR Surgical Q4 2024 earnings miss, stock plunges
STAA.O
-2.07%Positive
The earnings call reveals several concerns: a 3% net sales decline, significant losses in China, a net loss for fiscal 2024, and declining gross margins. The lack of a shareholder return plan and elevated inventory levels further dampen sentiment. Despite some optimism about future growth and the U.S. market, the Q&A session highlights uncertainties, particularly regarding competition and revenue recognition. The market cap suggests a moderate reaction, leading to a prediction of a negative stock price movement of -2% to -8% over the next two weeks.
